| Medication Name | Epclusa |
| Generic Name | Sofosbuvir/Velpatasvir |
| Boxed/Label Warning | Reactivation of Hepatitis B Virus (HBV) has been reported in HCV/HBV co-infected patients who are undergoing or have completed treatment with direct-acting antivirals for HCV and are not receiving HBV antiviral therapy. Screen all patients for evidence of current or prior HBV infection before initiating treatment with Epclusa. HBV reactivation has resulted in serious hepatic outcomes, including fulminant hepatitis, hepatic failure, and death. |
| Purpose | Treatment of chronic hepatitis C virus (HCV) infection in adults. |
| Mechanism of Action | Sofosbuvir inhibits HCV NS5B RNA-dependent RNA polymerase. Velpatasvir inhibits HCV NS5A protein. |
| Dosage Forms | Oral tablets |
| Available Strengths | Sofosbuvir 400 mg/Velpatasvir 100 mg |
| Dosage Frequency | Once daily |
| Common Side Effects | Headache, fatigue |
| Serious Side Effects | Hepatitis B virus reactivation, symptomatic bradycardia (when coadministered with amiodarone), liver failure (rare) |
| Drug Interactions | Amiodarone, rifampin, St. John’s Wort, carbamazepine, phenytoin, oxcarbazepine, tipranavir/ritonavir, elbasvir/grazoprevir, cyclosporine, rosuvastatin, digoxin |
| Important Notes | Screen all patients for HBV before starting Epclusa. Avoid coadministration with certain drugs. Consult your doctor about all medications you are taking. |
| Storage | Store at room temperature, between 68°F to 77°F (20°C to 25°C). |
| Missed Dose | Take the missed dose as soon as you remember on the same day. If you don’t remember until the next day, skip the missed dose and go back to your regular schedule. Do not take two doses at once. |
| Alternatives | Mavyret (glecaprevir/pibrentasvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) |